Chronic myelogenous leukemia.
Kalidas
M
M
Department of Bioimmunotherapy, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 422, Houston, TX 77030, USA. mtalpaz@mail.mdanderson.org
Kantarjian
H
H
Talpaz
M
M
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D016313:Genes, abl; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate